Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma

http://onlinelibrary.wiley.com/doi/...nticated=false&deniedAccessCustomisedMessage=

Another interesting data set for HCC. Even with the SIRT arm showing slightly less Median OS, the figures for survival at 1,2 & 3 years, looks very promising. Slightly larger trial with > 70 pts. My bolding of text.

These small trial data sets must give some hope for good data from the larger HCC trials.

Results

Median overall survivals of the two groups were comparable, being 14.4 months (95% CI: 4.3–24.5) in sorafenib and 13.2 months (95% CI: 6.1–20.2) in TARE patients, with 1-, 2- and 3-year survival rates of 52.1%, 29.3% and 14.7% vs 51.8%, 27.8% and 21.6% respectively. Two TARE patients underwent liver transplantation after successful down-staging. To minimize the impact of confounding factors on survival analysis, propensity model matched 32 patients of each group for median age, tumour gross pathology and the independent prognostic factors (portal vein thrombosis, performance status, Model for End Liver Disease). Even after matching, the median survival did not differ between sorafenib (13.1 months; 95% CI: 1.2–25.9) and TARE patients (11.2 months; 95% CI: 6.7–15.7), with comparable 1-, 2- and 3-year survival rates.
Conclusions

In cirrhotic patients with intermediate-advanced or not-otherwise-treatable HCC, sorafenib and TARE provide similar survivals. Down-staging allowing liver transplantation only occurred after TARE.